Filtered By:
Specialty: Drugs & Pharmacology
Condition: Disability

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 355 results found since Jan 2013.

The role of stem cell factor and granulocyte-colony stimulating factor in treatment of stroke.
This article summarizes the discovery of new routes of treatment for acute and chronic stroke using two hematopoietic growth factors, stem cell factor (SCF) and granulocyte-colony stimulating factor (G-CSF). In a study of acute stroke, SCF and G-CSF alone or in combination displays neuroprotective effects in an animal model of stroke. SCF appears to be the optimal treatment for acute stroke as the functional outcome is superior to G-CSF alone or in combination (SCF+G-CSF); however, SCF+G-CSF does show better functional recovery than G-CSF. In a chronic stroke study, the therapeutic effects of SCF and G-CSF alone or in comb...
Source: Recent Patents on CNS Drug Discovery - November 20, 2014 Category: Drugs & Pharmacology Tags: Recent Pat CNS Drug Discov Source Type: research

Development, Validation of LC-MS/MS Method and Determination of Pharmacokinetic Parameters of the Stroke Neuroprotectant Neurounina-1 in Beagle Dog Plasma After Intravenous Administration
Conclusion The developed and validated method to quantify neurounina-1 in beagle dog plasma using LC-MS/MS presented sensitivity and selectivity, thus allowing the rapid and precise determination of the pharmacokinetics of this neuroprotective compound working in the low nanomolar range. Ethics Statement This study was carried out in accordance with the recommendations of the general ethical guidelines established by the Brazilian Society for Laboratory Animal Science (SBCAL). The protocol was approved by the Committee for Ethics in Animal Use – State University of Campinas (CEUA/UNICAMP, protocol n° 3340-...
Source: Frontiers in Pharmacology - April 24, 2019 Category: Drugs & Pharmacology Source Type: research

Knowledge of stroke and medication adherence among patients with recurrent stroke or transient ischemic attack in Indonesia: a multi-center, cross-sectional study
ConclusionStroke knowledge was low among Indonesian stroke survivors and independently related to medication adherence. Attempts should be made to increase stroke knowledge which may improve medication adherence among stroke survivors.
Source: International Journal of Clinical Pharmacy - October 29, 2020 Category: Drugs & Pharmacology Source Type: research

Angiogenesis-Regulating microRNAs and Ischemic Stroke.
Abstract Stroke is a leading cause of death and disability worldwide. Ischemic stroke is the dominant subtype of stroke and results from focal cerebral ischemia due to occlusion of major cerebral arteries. Thus, the restoration or improvement of reduced regional cerebral blood supply in a timely manner is very critical for improving stroke outcomes and post-stroke functional recovery. The recovery from ischemic stroke largely relies on appropriate restoration of blood flow via angiogenesis. Newly formed vessels would allow increased cerebral blood flow, thus increasing the amount of oxygen and nutrients delivered ...
Source: Current Vascular Pharmacology - May 13, 2013 Category: Drugs & Pharmacology Authors: Yin KJ, Hamblin M, Chen YE Tags: Curr Vasc Pharmacol Source Type: research

A Review on Preclinical Models of Ischemic Stroke: Insights Into the Pathomechanisms and New Treatment Strategies
CONCLUSION: There are still many inter-linked pathophysiological alterations with regards to stroke, animal models need not necessarily mimic the same conditions of stroke pathology and newer targets and therapies are the need of the hour in stroke research.PMID:34493185 | DOI:10.2174/1570159X19666210907092928
Source: Current Neuropharmacology - September 8, 2021 Category: Drugs & Pharmacology Authors: Aditya A Singh Akash Kharwar Manoj P Dandekar Source Type: research

An audit of the pharmacological management of ischaemic stroke patients in a metropolitan Australian hospital
Conclusion The majority of the cohort was discharged on the appropriate evidence based medications for the management of secondary stroke. Further improvement may be achieved by pharmacist intervening as part of a multidisciplinary team.
Source: International Journal of Clinical Pharmacy - January 31, 2015 Category: Drugs & Pharmacology Source Type: research

Angiogenesis-regulating microRNAs and Ischemic Stroke.
Abstract Stroke is a leading cause of death and disability worldwide. Ischemic stroke is the dominant subtype of stroke and results from focal cerebral ischemia due to occlusion of major cerebral arteries. Thus, the restoration or improvement of reduced regional cerebral blood supply in a timely manner is very critical for improving stroke outcomes and poststroke functional recovery. The recovery from ischemic stroke largely relies on appropriate restoration of blood flow via angiogenesis. Newly formed vessels would allow increased cerebral blood flow, thus increasing the amount of oxygen and nutrients delivered t...
Source: Current Vascular Pharmacology - July 11, 2015 Category: Drugs & Pharmacology Authors: Yin KJ, Hamblin M, Chen YE Tags: Curr Vasc Pharmacol Source Type: research

Glucagon-like receptor 1 agonists and DPP-4 inhibitors: Anti-diabetic drugs with anti-stroke potential.
Abstract Stroke is one of the leading causes of death and serious disability in Westernized societies. The risk of stroke approximately doubles with each decade after the age of 55. Therefore, even though the incidence of stroke is declining, mostly because of the efforts to lower blood pressure and reduce smoking, the overall number of strokes is increasing due to the aging of the population. While stroke prevention by healthy lifestyle is effective in decreasing the risk of stroke, post stroke pharmacological strategies aimed at minimizing stroke-induced brain damage and promoting recovery are highly needed. Unf...
Source: Neuropharmacology - August 17, 2017 Category: Drugs & Pharmacology Authors: Darsalia V, Klein T, Nyström T, Patrone C Tags: Neuropharmacology Source Type: research

Caveolin-1 in stroke neuropathology and neuroprotection: a novel molecular therapeutic target for ischemic-related injury.
Abstract Cardiovascular disease and associated cerebral stroke are a global epidemic attributed to genetic and epigenetic factors, such as diet, life style and an increasingly sedentary existence due to technological advances in both the developing and developed world. There are approximately 5.9 million stroke-related deaths worldwide annually. Current epidemiological data indicate that nearly 16.9 million people worldwide suffer a new or recurrent stroke yearly. In 2014 alone, 2.4% of adults in the United States (U.S.) were estimated to experience stroke, which is the leading cause of adult disability and the fi...
Source: Current Vascular Pharmacology - February 5, 2018 Category: Drugs & Pharmacology Authors: Wang S, Head BP Tags: Curr Vasc Pharmacol Source Type: research

Risk of Stroke After Transcatheter Aortic Valve Implantation: Epidemiology, Mechanism, and Management
Conclusions: The overall evidences confirm similar or lower rate of stroke in TAVI versus SAVR. Risk predictors for acute stroke after TAVI are generally related to procedural factors, whereas late stroke is mainly associated with patient characteristics, with a variable impact on cognitive function. The optimal choice for the antithrombotic treatment in TAVI for stroke prevention is yet to be determined. Current data do not support routine use of cerebral embolic protection devices during TAVI.
Source: American Journal of Therapeutics - September 1, 2021 Category: Drugs & Pharmacology Tags: Therapeutic Advances Source Type: research

Genetic Signatures in the Treatment of Stroke.
Abstract Stroke is the fourth leading cause of mortality and neurological disability. It is caused by an intricate interplay of environmental and genetic factors. Genes not only influence susceptibility to stroke but have also been found to alter the response to pharmacological agents and may also influence the clinical outcome of the disease. Current treatment strategies for stroke include tissue plasminogen activator, antiplatelet agents and lipid lowering drugs. These act via diverse mechanisms of actions and are centered around the management of modifiable risk factors to prevent the recurrent stroke events. H...
Source: Current Pharmaceutical Design - August 26, 2014 Category: Drugs & Pharmacology Authors: Munshia A, Sharma V Tags: Curr Pharm Des Source Type: research

Cell-based and pharmacological neurorestorative therapies for ischemic stroke.
Abstract Ischemic stroke remains one of most common causes of death and disability worldwide. Stroke triggers a cascade of events leading to rapid neuronal damage and death. Neuroprotective agents that showed promise in preclinical experiments have failed to translate to the clinic. Even after decades of research, tPA remains the only FDA approved drug for stroke treatment. However, tPA is effective when administered 3-4.5 h after stroke onset and the vast majority of stroke patients do not receive tPA therapy. Therefore, there is a pressing need for novel therapies for ischemic stroke. Since stroke induces rapid...
Source: Neuropharmacology - August 31, 2017 Category: Drugs & Pharmacology Authors: Venkat P, Shen Y, Chopp M, Chen J Tags: Neuropharmacology Source Type: research

Sodium-glucose cotransporter 2 inhibitors and ischemic stroke.
CONCLUSION: Despite the multiple pleiotropic effects of SGLT-2 inhibitors, these agents do not appear to affect stroke risk. Ongoing large trials with longer follow-up will evaluate whether the pleiotropic effects of this class will translate into benefits in ischemic stroke prevention. PMID: 29412119 [PubMed - as supplied by publisher]
Source: Cardiovascular and Hematological Disorders Drug Targets - February 9, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

New understanding of the pathogenesis and treatment of stroke-related sarcopenia.
This article reviews the latest progress in the pathogenesis, screening, evaluation and treatment of stroke-related sarcopenia to provide reference for clinical treatment and rehabilitation of stroke. PMID: 32920517 [PubMed - as supplied by publisher]
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 9, 2020 Category: Drugs & Pharmacology Authors: Li W, Yue T, Liu Y Tags: Biomed Pharmacother Source Type: research